Advertisement

Association of Circulating Oxidized Lipids with Cardiovascular Outcomes

  • Irena LevitanEmail author
  • Ibra S. Fancher
  • Evgeny Berdyshev
Chapter
Part of the Translational Bioinformatics book series (TRBIO, volume 14)

Abstract

Multiple studies established the causal relationship between elevated levels of low density lipoproteins (LDL) and their oxidized modifications, oxidized LDL, and atherosclerosis. However, while it is generally recognized that LDL oxidation occurs mainly in the sub-endothelial space within the vascular wall, the role of circulating oxLDL in the development of the disease remains a matter of debate. There is also significant confusion in the field regarding the levels of oxLDL that occur in vivo, partly because of the complex and heterogeneous nature of the oxLDL particle and the discrepancies between the methods used for its detection. In this chapter, therefore, we first present different analytical methods used to evaluate the level, the state of oxidation and the lipid composition of oxLDL, which represents the basis of the lipidomics analysis of the circulating LDL. This is followed by presenting the current state of knowledge about the levels of circulating oxLDL and its two major components, oxidized phospholipids, oxPCs and oxysterols in human plasma and their association with the cardiovascular outcomes across multiple studies and cohorts of patients. Taken together, these studies present strong evidence for the circulating oxLDL and specific oxysterols to constitute independent risk factors for the development of atherosclerosis.

Notes

Acknowledgements

We are grateful to Mr. Gregory Kowalsky for helping with the preparation of the figures. This study is supported by NIH grants HL-073965 and HL-083298 to I.L.

References

  1. Arca M, et al. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radic Biol Med. 2007;42(5):698–705.CrossRefPubMedGoogle Scholar
  2. Ayee MA, et al. Molecular-scale biophysical modulation of an endothelial membrane by oxidized phospholipids. Biophys J. 2017;112(2):325–38.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Babaev VR, et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2000;20(12):2593–9.CrossRefPubMedGoogle Scholar
  4. Bertoia ML, et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol. 2013;61(21):2169–79.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Birukova AA, et al. Afadin controls p120-catenin-ZO-1 interactions leading to endothelial barrier enhancement by oxidized phospholipids. J Cell Physiol. 2012;227(5):1883–90.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Birukova AA, et al. Fragmented oxidation products define barrier disruptive endothelial cell response to OxPAPC. Transl Res. 2013;161(6):495–504.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bochkov VN, et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 2002;419(6902):77–81.CrossRefPubMedGoogle Scholar
  8. Bonacci G, et al. Conjugated linoleic acid is a preferential substrate for fatty acid nitration. J Biol Chem. 2012;287(53):44071–82.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Brooks CJW, et al. Profile analysis of oxygenated sterols in plasma and serum. Biochem Soc Trans. 1983;11:700–1.CrossRefGoogle Scholar
  10. Byfield FJ, et al. OxLDL increases endothelial stiffness, force generation and network formation. J Lipid Res. 2006;47:715–23.CrossRefPubMedGoogle Scholar
  11. Carantoni M, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol. 1998;18(5):762–7.CrossRefPubMedGoogle Scholar
  12. Chatterjee S, et al. Identification of a biologically active component in minimally oxidized low density lipoprotein (MM-LDL) responsible for aortic smooth muscle cell proliferation. Glycoconj J. 2004;20(5):331–8.CrossRefPubMedGoogle Scholar
  13. Chen NG, et al. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis. 2000;152(1):203–8.CrossRefPubMedGoogle Scholar
  14. Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191–212.PubMedPubMedCentralGoogle Scholar
  15. Domingues MR, Reis A, Domingues P. Mass spectrometry analysis of oxidized phospholipids. Chem Phys Lipids. 2008;156(1–2):1–12.CrossRefPubMedGoogle Scholar
  16. Dzeletovic S, et al. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem. 1995;225(1):73–80.CrossRefPubMedGoogle Scholar
  17. Ehara S, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103(15):1955–60.CrossRefPubMedGoogle Scholar
  18. Esterbauer H, et al. Inhibition of LDL oxidation by antioxidants. EXS. 1992a;62:145–57.PubMedGoogle Scholar
  19. Esterbauer H, et al. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992b;13(4):341–90.CrossRefPubMedGoogle Scholar
  20. Febbraio M, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105(8):1049–56.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Fraley AE, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009;53(23):2186–96.CrossRefPubMedGoogle Scholar
  22. Freyschuss A, et al. Vitamin C reduces cholesterol-induced microcirculatory changes in rabbits. Arterioscler Thromb Vasc Biol. 1997;17(6):1178–84.CrossRefPubMedGoogle Scholar
  23. Girard A, Sandulesco G. Sur une nouvelle série de réactifs du groupe carbonyle, leur utilisation à l’extraction des substances cétoniques et à la caractérisation microchimique des aldéhydes et cétones. Helv Chim Acta. 1936;19:1095.CrossRefGoogle Scholar
  24. Griffiths WJ, et al. New methods for analysis of oxysterols and related compounds by LC-MS. J Steroid Biochem Mol Biol. 2016;162:4–26.CrossRefPubMedGoogle Scholar
  25. Harats D, et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20(9):2100–5.CrossRefPubMedGoogle Scholar
  26. Hevonoja T, et al. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta (BBA) – Mol Cell Biol Lipids. 2000;1488(3):189–210.CrossRefGoogle Scholar
  27. Hodis HN, Crawford DW, Sevanian A. Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: further evidence for the role of cholesterol oxidation in atherosclerosis. Atherosclerosis. 1991;89(2–3):117–26.CrossRefPubMedGoogle Scholar
  28. Holvoet, P., Oxidized LDL:Role in cardiovascular risk and disease. In: Kovala, PP, editor. Cholesterol in atherosclerosis and coronary arery disease. 2005. p. 29–44.Google Scholar
  29. Holvoet P, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996;76(5):663–9.CrossRefPubMedGoogle Scholar
  30. Holvoet P, et al. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol. 1998a;18(1):100–7.CrossRefPubMedGoogle Scholar
  31. Holvoet P, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998b;98(15):1487–94.CrossRefPubMedGoogle Scholar
  32. Holvoet P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21(5):844–8.CrossRefPubMedGoogle Scholar
  33. Holvoet P, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53(4):1068–73.CrossRefPubMedGoogle Scholar
  34. Honda A, et al. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res. 2009;50(2):350–7.CrossRefPubMedGoogle Scholar
  35. Hörkkö S, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid–protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Investig. 1999;103(1):117–28.CrossRefPubMedGoogle Scholar
  36. Huo Y, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;110(14):2024–31.CrossRefPubMedGoogle Scholar
  37. Imazu M, et al. Plasma levels of oxidized low density lipoprotein are associated with stable angina pectoris and modalities of acute coronary syndrome. Int Heart J. 2008;49(5):515–24.CrossRefPubMedGoogle Scholar
  38. Itabe H, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem. 1994;269(21):15274–9.PubMedGoogle Scholar
  39. Itabe H, et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996;37(1):45–53.PubMedGoogle Scholar
  40. Itabe H, Obama T, Kato R. The dynamics of oxidized LDL during atherogenesis. J Lipid. 2011;2011:9.CrossRefGoogle Scholar
  41. Iuliano L. Pathways of cholesterol oxidation via non-enzymatic mechanisms. Chem Phys Lipids. 2011;164(6):457–68.CrossRefPubMedGoogle Scholar
  42. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990;9(6):515–40.CrossRefPubMedGoogle Scholar
  43. Jiang X, Ory DS, Han X. Characterization of oxysterols by electrospray ionization tandem mass spectrometry after one-step derivatization with dimethylglycine. Rapid Commun Mass Spectrom. 2007;21(2):141–52.CrossRefPubMedPubMedCentralGoogle Scholar
  44. Kagan VE, et al. Cardiolipin asymmetry, oxidation and signaling. Chem Phys Lipids. 2014;179:64–9.CrossRefPubMedGoogle Scholar
  45. Ke Y, et al. Anti-inflammatory effects of OxPAPC involve endothelial cell-mediated generation of LXA4. Circ Res. 2017;121(3):244–57.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Kuroki S, et al. Serum 7 alpha-hydroxycholesterol as a new parameter of liver function in patients with chronic liver diseases. Hepatology. 1995;22(4 Pt 1):1182–7.PubMedGoogle Scholar
  47. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition and pathophysiology. Antioxid Redox Signal. 2010;13:39–75.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Liebisch G, et al. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta. 2006;1761(1):121–8.CrossRefPubMedGoogle Scholar
  49. Liu S, Sjovall J, Griffiths WJ. Neurosteroids in rat brain: extraction, isolation, and analysis by nanoscale liquid chromatography-electrospray mass spectrometry. Anal Chem. 2003;75(21):5835–46.CrossRefPubMedGoogle Scholar
  50. Ma Z, et al. Inhibition of LPS- and CpG DNA-induced TNF-alpha response by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L808–16.CrossRefPubMedGoogle Scholar
  51. Maciel E, et al. Evaluation of oxidation and glyco-oxidation of 1-palmitoyl-2-arachidonoyl-phosphatidylserine by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;929:76–83.CrossRefPubMedGoogle Scholar
  52. Mehta JL, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100(11):1634–42.CrossRefPubMedGoogle Scholar
  53. Murphy RC. Steroids tandem mass spectrometry of lipids: molecular analysis of complex lipids. Cambridge: Royal Society of Chemistry; 2014. p. 233–73.Google Scholar
  54. Naruko T, et al. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol. 2006;26(4):877–83.CrossRefPubMedGoogle Scholar
  55. Nonas S, et al. Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo. Crit Care. 2008;12(1):R27.CrossRefPubMedPubMedCentralGoogle Scholar
  56. O’Donnell VB. Mass spectrometry analysis of oxidized phosphatidylcholine and phosphatidylethanolamine. Biochim Biophys Acta. 2011;1811(11):818–26.CrossRefPubMedGoogle Scholar
  57. Oda H, et al. Esterified and total 7 alpha-hydroxycholesterol in human serum as an indicator for hepatic bile acid synthesis. J Lipid Res. 1990;31(12):2209–18.PubMedGoogle Scholar
  58. Oh M-J, et al. Oxidized LDL signals through Rho-GTPase to induce endothelial cell stiffening and promote capillary formation. J Lipid Res. 2016;57(5):791–808.CrossRefPubMedPubMedCentralGoogle Scholar
  59. Palinski W, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98(3):800–14.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Parthasarathy S, et al. Lipid peroxidation and decomposition–conflicting roles in plaque vulnerability and stability. Biochim Biophys Acta. 2008;1781(5):221–31.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Pulfer M, Murphy RC. Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev. 2003;22(5):332–64.CrossRefPubMedGoogle Scholar
  62. Reis A, Spickett CM. Chemistry of phospholipid oxidation. Biochim Biophys Acta. 2012;1818(10):2374–87.CrossRefPubMedGoogle Scholar
  63. Sakaguchi H, et al. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Investig. 1998;78(4):423–34.PubMedGoogle Scholar
  64. Schroepfer GJ Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev. 2000;80(1):361–554.CrossRefPubMedGoogle Scholar
  65. Shentu TP, et al. oxLDL-induced decrease in lipid order of membrane domains is inversely correlated with endothelial stiffness and network formation. Am J Physiol Cell Physiol. 2010;299(2):C218–29.CrossRefPubMedPubMedCentralGoogle Scholar
  66. Sidhu R, et al. A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid. J Lipid Res. 2015;56(6):1222–33.CrossRefPubMedPubMedCentralGoogle Scholar
  67. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med. 2002;252(5):440–7.CrossRefPubMedGoogle Scholar
  68. Song J, et al. Association of plasma 7-ketocholesterol with cardiovascular outcomes and total mortality in patients with coronary artery disease. Circ Res. 2017;120(10):1622–31.CrossRefPubMedGoogle Scholar
  69. Spickett CM, Pitt AR. Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology. Antioxid Redox Signal. 2015;22(18):1646–66.CrossRefPubMedPubMedCentralGoogle Scholar
  70. Steinberg D, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–24.CrossRefPubMedGoogle Scholar
  71. Subbanagounder G, et al. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol. 2000;20(10):2248–54.CrossRefPubMedGoogle Scholar
  72. Tsimikas S, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360–70.CrossRefPubMedGoogle Scholar
  73. Tsimikas S, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006;47(11):2219–28.CrossRefPubMedGoogle Scholar
  74. Tsimikas S, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56(12):946–55.CrossRefPubMedGoogle Scholar
  75. Tyurina YY, et al. Characterization of cardiolipins and their oxidation products by LC-MS analysis. Chem Phys Lipids. 2014;179:3–10.CrossRefPubMedGoogle Scholar
  76. Van Tits L, et al. Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Investig. 2003;83(1):13–21.CrossRefPubMedGoogle Scholar
  77. van Tits LJ et al. Proportion of oxidized ldl relative to plasma apolipoprotein b does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2005. [Epub ahead of print].Google Scholar
  78. Watson AD, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272(21):13597–607.CrossRefPubMedGoogle Scholar
  79. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785–92.CrossRefPubMedPubMedCentralGoogle Scholar
  80. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001;11(3–4):93–102.CrossRefPubMedGoogle Scholar
  81. Yan X, et al. Fatty acid epoxyisoprostane E2 stimulates an oxidative stress response in endothelial cells. Biochem Biophys Res Commun. 2014;444(1):69–74.CrossRefPubMedPubMedCentralGoogle Scholar
  82. Zhang C et al. OxLDL-induced endothelial proliferation via Rho/ROCK/Akt/p27kip1 signaling: prevention by cholesterol loading. Am J Physiol Cell Physiol. 2017: p. ajpcell 00249 2016.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Irena Levitan
    • 1
    Email author
  • Ibra S. Fancher
    • 1
  • Evgeny Berdyshev
    • 2
  1. 1.Division of Pulmonary and Critical Care, Department of MedicineUniversity of Illinois at ChicagoChicagoUSA
  2. 2.National Jewish Health, Department of Medicine, Division of PulmonaryCritical Care and Sleep MedicineDenverUSA

Personalised recommendations